2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/19/17INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2
PHOENIX, Oct. 19, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today announced that it will release its third quarter 2017 financial results on Thursday, Nov. 2, before the U.S. financial markets open. Following the release of the financial results, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 8:30 a.m. Eastern Daylight Time. Investors, analysts and members of t... 
Printer Friendly Version
10/09/17INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit
PHOENIX, Oct. 09, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the Oppenheimer Specialty Pharma Summit to be held Oct. 11, 2017 at the Sofitel Hotel in New York. Management will provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference. The ... 
Printer Friendly Version
10/09/17INSYS Therapeutics Extends ‘Compassionate Use’ Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy
Extension of Expanded Access Program Enables Patients from Initial Trials to Continue Taking Investigational Medicine Under Their Physicians’ Supervision PHOENIX, Oct. 09, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it has extended the compassionate use studies of its proprietary oral formulation of cannabidiol (CBD) for the treatment of refractory pediatric epilepsy, enabling patients from previous clinical trials of the in... 
Printer Friendly Version
10/06/17INSYS Therapeutics Addresses New Jersey Complaint
PHOENIX, Oct. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We would like to reiterate that we continue to work with relevant authorities to resolve issues related to inappropriate actions taken by some of our former employees. Accordingly, we have taken a series of major actions to prevent the mistakes of the past from happening in the future. With respect to the complaint filed by the New Jersey Atto... 
Printer Friendly Version
10/03/17INSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose
Results Show Favorable Effect of Company’s Novel Formulation, Similar to Intramuscular Administration; NDA Filing with FDA on Track for 2018 PHOENIX, Oct. 03, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its recently completed pharmacokinetics (PK) study of the company’s proprietary intranasal naloxone spray formulation for the treatment of opioid overdose showed favorable results, similar to those for the current standard of... 
Printer Friendly Version
09/29/17INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA
Advances R&D for promising portfolio of innovative medicines PHOENIX, Sept. 29, 2017 (GLOBE NEWSWIRE) -- In advancing its pipeline of innovative medicines, INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it filed a New Drug Application (NDA) for a novel formulation of buprenorphine as a sublingual spray for the management of moderate-to-severe acute pain with the U.S. Food and Drug Administration (FDA). “We believe that buprenorphine sublingual s... 
Printer Friendly Version
09/21/17INSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
PHOENIX, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”), today announced that Saeed Motahari, President and Chief Executive Officer, and Andrew Long, Chief Financial Officer, will present at the Cantor Fitzgerald Global Healthcare Conference as follows: Date:    Wednesday, September 27, 2017 Time: 4:35 p.m. Eastern Daylight Time Location:            InterContinental New York Barclay Hote... 
Printer Friendly Version
09/21/17INSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency
Increases commitment to engaging key stakeholder groups as Company continues development of pharmaceutical cannabinoids PHOENIX, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company"), today announced the hiring of Joe McGrath as the Company’s Senior Director of Corporate Communications, and the retention of the Alpha IR Group (“Alpha IR”) as its investor relations agency of record. McGrath joins INSYS Therapeutics after nearly 16 years in publ... 
Printer Friendly Version
09/01/17Insys Addresses Arizona Attorney General Complaint
PHOENIX, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We continue to reiterate our efforts to be part of the solution to the opioid crisis by focusing on assisting patients and developing alternative pain medications in our research and development programs. The solutions to this serious national challenge require serious commitment by, and coordination between, governmental authorities, manufact... 
Printer Friendly Version
08/22/17Insys Addresses Questions Raised by Illinois Settlement
PHOENIX, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: Like so many stakeholders in the healthcare community and in the government, we share the desire to address the serious national challenge related to the misuse and abuse of opioids that has led to addiction and unnecessary deaths and has caused so much pain to families and communities around the country.  Our recent settlement with the State ... 
Printer Friendly Version
08/03/17Insys Therapeutics Reports Second Quarter 2017 Results
PHOENIX, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company") today announced financial results for the three-month period ended June 30, 2017. Highlights of and subsequent to the second quarter of 2017 include: Total net revenue was $42.6 million, compared to $69.2 million for the second quarter of 2016;   Net loss totaled $8.2 million, or ($0.11) per basic and diluted share, compared to net income of $6.0 million, or $0.08 per basic ... 
Printer Friendly Version
07/31/17Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription
PHOENIX, July 31, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today announced that SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol, CII, is now available for health care professionals to prescribe.  SYNDROS is stocked with most of the major wholesalers for retail pharmacy ordering or through the INSYS Specialty Pharmacy Network. For more information, please call 1-844-309-3835. SYNDROS i... 
Printer Friendly Version
07/20/17Insys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017
PHOENIX, July 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its second quarter 2017 financial results on Thursday, August 3, 2017, before the U.S. financial markets open. Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Daylight Time. Interested parties ... 
Printer Friendly Version
07/18/17Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer
PHOENIX, July 18, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced today that Andrew G. Long has joined the company as Chief Financial Officer, effective August 7, 2017. Andrew G. Long is a seasoned finance executive with three decades of experience in the life sciences, bio-pharma and industrial sectors. Mr. Long brings to Insys a diverse set of experiences, which he honed at companies known for grooming best-in-class finance talent. His ... 
Printer Friendly Version
07/17/17Insys Therapeutics, Inc. Releases Statement on Payor Interactions
PHOENIX, July 17, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a statement today on its interactions with payors: Insys, in concert with its business partners, is dedicated to helping patients navigate the complex payor environment that exists for patients as they seek to access the Insys products that their practicing health care providers have deemed appropriate or necessary for their treatment.  As part of this endeavor, Insys is committ... 
Printer Friendly Version
06/20/17Insys Therapeutics Hires Four Key Pharmaceutical Industry Veterans for Leadership Positions
PHOENIX, June 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced the addition of four pharmaceutical industry veterans to its management team. Joining Insys are: Brian Jennings, Vice President of Sales Dr. Dean Mariano, Senior Director, Clinical Development/Medical Affairs; Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and Managed Care; and, Scott Warlick, General Manager, Manufacturing “These key hire... 
Printer Friendly Version
06/05/17Insys Therapeutics, Inc. Releases Statement on Its Ongoing Mission
PHOENIX, June 05, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a response to the recent media reports that highlight concerns with the Company’s past commercial practices and former employees. Insys reiterates its commitment to: maintaining the highest ethical standards and compliance around all its activities and business practices and complying with governing laws and regulations; providing innovative solutions related to patient c... 
Printer Friendly Version
05/31/17Insys Therapeutics, Inc. to Present at June Conferences
PHOENIX, May 31, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Saeed Motahari, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the following healthcare conferences in June: Conference:       Jefferies 2017 Global Healthcare Conference Date:       Thursday, June 8, 2017 Time:       1... 
Printer Friendly Version
05/24/17Insys Therapeutics, Inc. Announces FDA Final Product Label for Syndros
Launch Planned for August 2017 PHOENIX, May 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the final product label for Syndros™ (dronabinol) oral solution, CII, a liquid formulation of the pharmaceutical cannabinoid, dronabinol.  Syndros is approved for use in treating anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (“AIDS”) ... 
Printer Friendly Version
05/16/17Insys Therapeutics Announces Chief Financial Officer Transition
PHOENIX, May 16, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Darryl S. Baker, the Company's Chief Financial Officer (“CFO”), will transition from the role of CFO when a successor is hired. Insys has engaged an executive search firm to support the recruitment of a new CFO. Mr. Baker will continue to work closely with the management team, including the new CFO, to facilitate a smooth and successful transition of his responsib... 
Printer Friendly Version
05/09/17Insys Therapeutics Reports First Quarter 2017 Results
PHOENIX , May 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended March 31, 2017 . Highlights of and subsequent to the first quarter of 2017 include: Net revenue totaled $36.0 million , compared to $60.4 million for the first quarter of 2016;   Net loss of $6.5 million , or $(0.09) per basic and diluted share, compared to net income of $2.3 ... 
Printer Friendly Version
05/04/17Insys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors
PHOENIX, Ariz., May 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that Rohit Vishnoi, a seasoned healthcare executive, has been appointed to the Company’s Board of Directors, effective as of May 2, 2017.  Mr. Vishnoi has also been appointed to the Company’s Science and Research and Development Committee and Nominating and Corporate Governance Committee. “Rohit Vishnoi’s many assets include a proven track record of balancing strategy... 
Printer Friendly Version
04/25/17Insys Therapeutics to Report First Quarter 2017 Results on May 9, 2017
PHOENIX, April 25, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its first quarter 2017 financial results on Tuesday, May 9, 2017, before the U.S. financial markets open. Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Daylight Time. Interested parties may... 
Printer Friendly Version
04/24/17Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs
PHOENIX, April 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that effective today, Dr. Steven James will join the Company as Vice President of Medical Affairs. “Dr. James joins Insys with extensive research and development credentials and a proven record of accomplishments.  We believe he will play a critical role in achieving our mission of improving patients’ care by leveraging our proprietary sublingual spray platform and strong ... 
Printer Friendly Version
04/03/17Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results
PHOENIX, April 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December 31, 2016. Highlights of and subsequent to the fourth quarter of 2016 include: Total net revenue decreased to $54.9 million, compared to $93.9 million for the fourth quarter of 2015;   Net loss was $3.7 million, or $(0.05) per basic and diluted share, compared to net income of $18.1 million, ... 
Printer Friendly Version
03/27/17Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors. “We are excited that Saeed, a 20-year veteran of the life sciences industry, has chosen to bring his immense depth of sales and marketing, managed care, and commercial operations experience to In... 
Printer Friendly Version
03/23/17DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.  On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros. Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical O... 
Printer Friendly Version
03/15/17Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results
-- Fourth Quarter 2016 Net Sales Estimated at $54 million -- PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the Company will delay the release of its financial results for the fourth quarter and full year 2016.  The Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorde... 
Printer Friendly Version
03/02/17Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results
PHOENIX, March 02, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter and full year 2016 on Thursday, March 16, 2017, before the U.S. financial markets open. Following the release of the financial results, Dr. Santosh Vetticaden, Interim CEO, and Chief Medical Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Da... 
Printer Friendly Version
02/15/17Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study.  The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (... 
Printer Friendly Version
02/14/17Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference as follows: Date:   Thursday, February 23, 2017 Time:   1:35 p.m. Eastern Standard Time Location:   The New ... 
Printer Friendly Version
01/09/17Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive Officer (“CEO”) and Chairman of the Company’s Board of Directors (“Board”) will retire as President and CEO and Chairman effective January 9, 2017.  Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board.  In connection ... 
Printer Friendly Version
01/04/17Insys Therapeutics, Inc. to Present at J.P. Morgan 35th Annual Healthcare Conference
PHOENIX, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the J.P. Morgan 35th Annual Healthcare Conference as follows: Date:   Monday, January 9, 2017   Time:   4:00 p.m. Pacific Standard Time   Location:   We... 
Printer Friendly Version